EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia

Maurizio Aricò iD

Pediatric Reports · 17.06.2026 · 18 (3) · 82

DOI: 10.3390/pediatric18030082 ↗

Kurz gefasst

Kommentar in der Zeitschrift Pediatric Reports, online erschienen am 17.06.2026. Verfasst von Maurizio Aricò. Beteiligte Einrichtung: Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombopoietin receptor agonists (TPO-RAs) have become central second-line treatments for children with persistent or chronic immune thrombocytopenia (ITP). Their efficacy has encouraged broad use, but difficult-to-treat patients who respond suboptimally may be exposed to repeated agent switching, prolonged treatment, or doses exceeding approved limits. This commentary uses a focused narrative approach to address whether the risk of treatment-associated marrow fibrosis should be interpreted primarily as a consequence of treatment duration or as a risk marker linked to supraphysiological treatment intensity in non-responders. A recent Haematologica report by Ma and colleagues identified clinically significant bone marrow myelofibrosis in a highly selected cohort of children with chronic ITP undergoing marrow re-evaluation after suboptimal response or loss of efficacy during TPO-RA therapy. The most relevant message is not simply that fibrosis can occur, but that it was independently associated with treatment intensification, particularly overdose and frequent switching. The biological plausibility of this association is supported by the known capacity of sustained megakaryocytic stimulation to promote local pro-fibrotic signaling and reticulin deposition. This commentary places this safety concern in the context of pediatric ITP epidemiology, current regulatory indications, expert approaches to refractory disease, and practical surveillance considerations. TPO-RAs should not be viewed as routine treatment for newly diagnosed pediatric ITP; their principal role remains in selected children with persistent or chronic disease who require second-line therapy. Failure to respond at the maximum approved dose should prompt diagnostic and therapeutic reassessment rather than automatic treatment escalation. The emerging lesson is that response-adapted therapy must also be risk-adapted therapy.

Schlagwörter

Stichwörter der Autor:innen

avatrombopagdrug safetyeltrombopagimmune thrombocytopeniamyelofibrosispediatric hematologyrefractory ITPromiplostimthrombopoietin receptor agoniststreatment intensification

Autor:innen und Institutionen

  • Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy.

ORCID-Profile: Maurizio Aricò

Zitieren

APA

Aricò, M. (2026). When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia. Pediatric Reports, 18(3), 82. https://doi.org/10.3390/pediatric18030082

Vancouver

Aricò M. When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia. Pediatric Reports. 2026;18(3):82. doi:10.3390/pediatric18030082

BibTeX
@article{Aric2026,
  author = {Aricò, Maurizio},
  title = {When Platelet Stimulation Becomes Marrow Stress: Rethinking Thrombopoietin Receptor Agonist Intensification in Pediatric Immune Thrombocytopenia},
  journal = {Pediatric Reports},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {82},
  doi = {10.3390/pediatric18030082}
}
Kostenlos starten →